pharmacotherapy updates of recombinant tissue plasminogen activator (r-tpa) in acute ischemic stroke
Authors
abstract
conclusions due to considerable inter- and intra- heterogeneity among studies performed by other centers such as differences in study project, background, and population features, determining a pharmacotherapy model based on safe implementation of treatments in stroke or sits seem advantageous. results age, time of onset, systolic blood pressure, diabetes, stroke severity, co-morbidities and premorbid medical situation, stroke scale according to national institute of health and outcomes related to ct (head, angiogram and perfusion) were considered when determining successful treatment by endovascular thrombectomy. according to the 2015 guidelines, strategies related to successful pharmacotherapy management should be based on class i evidence-care on a stroke unit, iv-r-tpa within 3 - 4.5 hours of stroke onset, aspirin commenced within 48 hours of stroke onset, and decompressive cranioctomy for supratentorial malignant hemispheric cerebral infarction. hemorrhagic stroke (intraparenchymal, subarachnoid, intraventricular, intracerebral such as orolingual angioedema), hematoma (epidural and subdural) and head trauma are the absolute contraindications related to r-tpa prescription. evidence acquisition searches for associated published articles were conducted in major databases until september 2015. the main terms used in the search were a combination of words and phrases such as ischemic stroke and tissue plasminogen activator. context according to published articles, thrombosis is the main reason for death all over of the world. with stroke time missing is brain missing, therefore, the fda-approved drug r-tpa, could be administered as initial iv bolus in less than 3 - 4.5 hours from onset of acute ischemic stroke (ais). the aim of this review was to provide updated pharmacotherapy related to r-tpa in ais.
similar resources
The Outcome of Treatment With Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke
Background: Thrombolytic therapy is the recommended treatment of acute ischemic stroke. It is crucial to evaluate the treatment results with recombinant Tissue Plasminogen Activator (r-TPA) in patients with acute stroke. Objectives: This study aimed to evaluate treatment outcomes with r-TPA in patients with acute stroke in a referral stroke center in Iran. Materials & Methods: In this retrosp...
full textthe effect of recombinant tissue plasminogen activator (r-tpa) on quantitation of neutralising anti-streptokinase antibodies
the measurement of anti-streptokinase antibodies can distinguish the patients who may benefit from streptokinase and those who should be treated with some other thrombolytic regimen. neutralising titration test is a commonly used classical assay for measuring anti-streptokinase antibodies and in this assay the ability of anti-streptokinase antibodies in patients' sera in preventing the lytic ef...
full textPilot randomized trial of tissue plasminogen activator in acute ischemic stroke. The TPA Bridging Study Group.
BACKGROUND AND PURPOSE Early thrombolytic therapy with recombinant tissue-type plasminogen activator is a theoretically attractive approach to the treatment of acute focal cerebral ischemia. In preparation for a larger multicenter trial, three centers piloted a protocol for a randomized, double-blind, placebo-controlled trial of intravenous recombinant tissue-type plasminogen activator begun wi...
full textCurrent perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke
In 1995, the NINDS (National Institute of Neurological Disorders and Stroke) tPA (tissue plasminogen activator) Stroke Study Group published the results of a large multicenter clinical trial demonstrating efficacy of intravenous tPA by revealing a 30% relative risk reduction (absolute risk reduction 11%-15%) compared with placebo at 90 days in the likelihood of having minimal or no disability. ...
full textRecombinant Tissue-Type Plasminogen Activator (Alteplase) for Ischemic Stroke
THE FOOD AND DRUG ADMINIStration (FDA) approval in June 1996 of intravenous recombinant tissue-type plasminogen activator (rt-PA) for patients with acute ischemic stroke treated within 3 hours of symptom onset marked a historic first step in treating this devastating disease. This approval was primarily based on the results of the National Institute of Neurologic Disorders (NINDS) trials (1 and...
full textAcute Ischemic Stroke After Recombinant Tissue Plasminogen Activator for Acute Myocardial Infarction
Introduction/Background: Occurrence of a cerebrovascular accident (CVA) after thrombolytic therapy for acute myocardial infarction (MI) is an uncommon but recognized clinical problem [1]. Although, intracranial hemorrhage is the primary neurological complication noted after thrombolytic therapy [2, 3], ischemic CVA is an infrequent and devastating complication that is reported to occur after 48...
full textMy Resources
Save resource for easier access later
Journal title:
jentashapir journal of health researchجلد ۷، شماره ۳، صفحات ۰-۰
Keywords
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023